• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

Queen’s-led European research project makes huge steps in tackling global health…

Bioengineer.org by Bioengineer.org
January 31, 2018
in Headlines, Health, Science News
Reading Time: 3 mins read
2
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Queen's University Belfast

Antibiotic resistance is an urgent global health issue, killing hundreds of thousands annually, a figure expected to rise to over 10 million by 2050.

The lack of antimicrobials and antiviral therapies combined with the very few new drugs that have entered the market in the past number of years emphasise the need for novel effective therapies. In recognising the urgency to address this global threat, the European Commission provided €4 million in funding to Queen's to coordinate INBIONET (Infection Biology Training Network). INBIONET brings together leading scientists across Europe from a range of disciplines including microbiology, immunology, cellular biology and biochemistry to tackle infections in its whole complexity. Professor Jose Bengoechea, Director of the Wellcome-Wolfson Institute for Experimental Medicine at Queen's and the project lead explains: "Antibiotic-resistance is fast becoming one of the major scientific and health issues of modern times. That is why consortia like the INBIONET are so important in bringing together researchers across Europe to bring their expertise to the table in tackling this global challenge."

Professor Andrew Bowie, Head of Immunology in the School of Biochemistry and Immunology, Trinity College Dublin said: "INBIONET was critical in developing a new network of scientists to examine host-pathogen interactions with a view to sharing different perspectives and hence developing new synergies. Already further grants have been leveraged based on INBIONET activity which will allow us to further exploit these synergies."

The project, which has now come to an end, has led to significant advances in understanding how different microbes evade our defences. The study found that a range of microbes (bacteria and viruses) that cause different infections share a common anti-immune strategy. Professor Bengoechea added: "We have discovered that various pathogens react the same way in trying to tackle crucial defence mechanisms of our body. This discovery suggests that potentially one drug counteracting this common anti-immune strategy could be used to treat different type of infections."

The research has also unveiled that proteins released to combat viruses known as interferons, play a significant role in fighting infections caused by bacteria. Interferons were used to treat an infection, Klebsiella pneumoniae, which was recently listed as an urgent threat to global health by the World Health Organisation. Professor Bengoechea said: "Without an alternative approach to treating anti-biotic resistant infections, we are faced with a potential epidemic. This research has discovered potentially a new therapeutics to treat Klebsiella infections, offering viable alternatives to treat viruses and infections that have high mortality rates.

"Through collaborative working we have made great strides in addressing a global health issue. We now hope to move quickly to clinical trial stage to do further tests on the discoveries made through this work. Many spin-off projects have been secured through this consortium too which will lead to further global medical advances in tackling infections."

Innovative testing models were developed through the INBIONET consortium including three-dimensional organoids that enable clinicians to assess how the immune system responds to bacteria known to cause gastric cancer. Other testing models include the development of an ex vivo lung infection model to investigate the killer infection, Klebsiella pneumoniae. These testing models give clinicians around the world the necessary tools to investigate much needed new therapeutics against these deadly infections.

The study was selected by the European Commission from several projects funded by the European Commission to exemplify the extraordinary impact this research has made in advancing our understanding of microbial strategies and its potential to shape the future treatments of infections.

###

Media Contact

Suzanne Lagan
[email protected]
0044-289-097-5292
@QueensUBelfast

http://www.qub.ac.uk

Original Source

http://cordis.europa.eu/result/rcn/197474_en.html

Share12Tweet7Share2ShareShareShare1

Related Posts

Reptile Tongue Movements Inspire Innovative Biomedical and Space Technology, Study Shows

September 8, 2025

Revolutionary Light-Powered Chip Enhances AI Task Efficiency by 100 Times

September 8, 2025

New Study Reveals Positive Impacts of Climate-Smart Agriculture Practices

September 8, 2025

Impact of Weight Bias on Diabetes Healthcare Experiences

September 8, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Reptile Tongue Movements Inspire Innovative Biomedical and Space Technology, Study Shows

Revolutionary Light-Powered Chip Enhances AI Task Efficiency by 100 Times

New Study Reveals Positive Impacts of Climate-Smart Agriculture Practices

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.